Association Between Gross Features and Coexistence of <i> BRAF <sup>V600E</sup> </i> and <i>TERT</i> Promoter Mutations in Papillary Thyroid Carcinomas: A Combined Analysis Incorporating Clinicopathologic Features

<b><i>Background:</i></b> The coexistence of v-Raf murine sarcoma viral oncogene homolog B1 (<i>BRAF<sup>V600E</sup></i>) and telomere reverse transcriptase promoter (<i>TERT</i>-p) mutations is considerably associated with aggressiveness and poor prognosis in papillary thyroid carcinoma (PTC). However, the association between gross findings and genetic alterations in PTC remains unknown. We aimed to investigate the association between clinicopathologic features, including macroscopic features, and the coexistent <i>BRAF<sup>V600E</sup></i> and <i>TERT</i>-p mutations in patients with PTC. <b><i>Methods:</i></b> We retrospectively analyzed 375 cases of PTC surgically resected between January 2018 and October 2023 at a single institution, based on the presence of <i>BRAF<sup>V600E</sup></i> and <i>TERT</i>-p double mutation. Clinicopathologic features, including gross features on the cut surface of tumors, were evaluated. Subsequently, the association between clinicopathologic features and mutation status was statistically examined. Cox proportional hazard models were used to analyze the impact of molecular pathological features on disease-free survival (DFS). <b><i>Results:</i></b> The <i>BRAF<sup>V600E</sup></i> and <i>TERT</i>-p double mutation was identified in 78 (20.8%) patients among the PTC cases and was significantly correlated with shorter DFS. Multivariable analysis revealed that factors such as relatively older age (≥55 years) (odds ratio [OR] = 12.083, 95% confidence interval [CI] 4.498-32.456), larger tumor size (>2.0 cm) (OR = 2.722, CI 1.104-6.712), lobulated tumor margins (OR = 16.114, CI 3.155-82.296), papillary excrescences on the cut surface (OR = 17.573, CI 3.462-89.201), solid-cut surface (OR = 4.012, CI 1.084-14.849), minimal extrathyroidal extension (ETE) (OR = 4.156, CI 1.209-14.282), gross ETE (OR = 6.517, CI 1.734-24.490), and Ki-67 labeling index (LI) (≥5%, OR = 12.145, CI 4.354-33.877) were significantly associated with the double mutation. <b><i>Conclusions:</i></b> The <i>BRAF<sup>V600E</sup></i> and <i>TERT</i>-p double mutation in PTC was significantly associated with relatively old age, larger tumor size, lobulated configuration in tumor margin, papillary excrescences on the cut surface, solid-cut surface, ETE, and high Ki-67 LI. These features are suggestive of the presence of the double mutation and should be analyzed at the molecular level in patients with PTC.

Authors

Institutions

Publication Details

Journal
Thyroid
Published
2024-10-31
DOI
https://doi.org/10.1089/thy.2024.0310
Citations
1
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.36
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association Between Gross Features and Coexistence of BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinomas: A Combined Analysis Incorporating Clinicopathologic Features

Nguyen Thi Nhung, Yuki Matsuoka, Hiroyuki Yamashita, Hirokazu Kurohama et al.
1 citations
Thyroid
Thyroid Cancer Diagnosis and Treatment
0.36
article

Association Between Gross Features and Coexistence of BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinomas: A Combined Analysis Incorporating Clinicopathologic Features

Nguyen Thi Nhung, Yuki Matsuoka, Hiroyuki Yamashita, Hirokazu Kurohama, Van Phu Thang Nguyen, Masahiro Nakashima, Yuko Akazawa, Zhanna Mussazhanova, Kenichi Yokota, Katsuya Matsuda, Thị Ngọc Anh Nguyễn, Shinya Satoh, Yerkerzhan Sailaubekova
article en
1 citations

Abstract

<b><i>Background:</i></b> The coexistence of v-Raf murine sarcoma viral oncogene homolog B1 (<i>BRAF<sup>V600E</sup></i>) and telomere reverse transcriptase promoter (<i>TERT</i>-p) mutations is considerably associated with aggressiveness and poor prognosis in papillary thyroid carcinoma (PTC). However, the association between gross findings and genetic alterations in PTC remains unknown. We aimed to investigate the association between clinicopathologic features, including macroscopic features, and the coexistent <i>BRAF<sup>V600E</sup></i> and <i>TERT</i>-p mutations in patients with PTC. <b><i>Methods:</i></b> We retrospectively analyzed 375 cases of PTC surgically resected between January 2018 and October 2023 at a single institution, based on the presence of <i>BRAF<sup>V600E</sup></i> and <i>TERT</i>-p double mutation. Clinicopathologic features, including gross features on the cut surface of tumors, were evaluated. Subsequently, the association between clinicopathologic features and mutation status was statistically examined. Cox proportional hazard models were used to analyze the impact of molecular pathological features on disease-free survival (DFS). <b><i>Results:</i></b> The <i>BRAF<sup>V600E</sup></i> and <i>TERT</i>-p double mutation was identified in 78 (20.8%) patients among the PTC cases and was significantly correlated with shorter DFS. Multivariable analysis revealed that factors such as relatively older age (≥55 years) (odds ratio [OR] = 12.083, 95% confidence interval [CI] 4.498-32.456), larger tumor size (>2.0 cm) (OR = 2.722, CI 1.104-6.712), lobulated tumor margins (OR = 16.114, CI 3.155-82.296), papillary excrescences on the cut surface (OR = 17.573, CI 3.462-89.201), solid-cut surface (OR = 4.012, CI 1.084-14.849), minimal extrathyroidal extension (ETE) (OR = 4.156, CI 1.209-14.282), gross ETE (OR = 6.517, CI 1.734-24.490), and Ki-67 labeling index (LI) (≥5%, OR = 12.145, CI 4.354-33.877) were significantly associated with the double mutation. <b><i>Conclusions:</i></b> The <i>BRAF<sup>V600E</sup></i> and <i>TERT</i>-p double mutation in PTC was significantly associated with relatively old age, larger tumor size, lobulated configuration in tumor margin, papillary excrescences on the cut surface, solid-cut surface, ETE, and high Ki-67 LI. These features are suggestive of the presence of the double mutation and should be analyzed at the molecular level in patients with PTC.

ThyroidVol. 34(12)
Nagasaki University (JP), Yamashita Thyroid Hospital
Openalex Percentile: Top 32%
Thyroid Cancer Diagnosis and Treatment
0.36
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.